Understand the source comparison
NAD+ for Smoking Cessation: Delivery Methods Comparison
Oral NAD+ (direct) <5%. Degraded in GI tract before absorption 250–500mg daily Minimal. Poor oral absorption limits CNS delivery Not recommended. Most NAD+ is broken down before systemic circulation Oral NR (precursor) 40–60%. Converts to NAD+ intracellularly
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Oral NAD+ (direct)
- <5%. Degraded in GI tract before absorption
- 250–500mg daily
- Minimal. Poor oral absorption limits CNS delivery
- Not recommended. Most NAD+ is broken down before systemic circulation
- Oral NR (precursor)
- 40–60%. Converts to NAD+ intracellularly
- 300–1,000mg daily
- Reaches therapeutic range in 7–14 days
- Most practical option for sustained supplementation. Evidence supports tissue NAD+ elevation
- Oral NMN (precursor)
- 30–50%. Converted via intestinal enzymes
- Comparable to NR with slightly faster kinetics
- Emerging evidence suggests equivalence to NR. Cost and availability vary
- IV NAD+ infusion
- 95–100%. Bypasses GI metabolism
- 500–1,000mg per session, 5–10 sessions over 10–14 days
- Immediate peak within 30–60 minutes
- Fastest route to tissue saturation. Expensive, clinic-dependent, short-term elevation unless paired with oral maintenance
- Sublingual NAD+
- 15–25%. Partial buccal absorption
- 50–100mg per dose, 2–3 times daily
- Moderate. Better than oral but inconsistent
- Limited published data. Anecdotal reports suggest benefit but pharmacokinetic studies are lacking
- NR and NMN remain the most studied oral NAD+ precursors with documented CNS penetration in human trials. IV protocols deliver rapid elevation but require clinical oversight and are cost-prohibitive for extended use.